MBX Biosciences, Inc. (MBX)
| Market Cap | 1.77B +323.7% |
| Revenue (ttm) | n/a |
| Net Income | -86.61M |
| EPS | -2.18 |
| Shares Out | 47.60M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,732,460 |
| Open | 31.33 |
| Previous Close | 30.99 |
| Day's Range | 30.51 - 37.27 |
| 52-Week Range | 9.43 - 45.85 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 69.09 (+85.48%) |
| Earnings Date | May 7, 2026 |
About MBX
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy fo... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for MBX stock is "Buy." The 12-month stock price target is $69.09, which is an increase of 85.48% from the latest price.
News
MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism
Responder rate of 57% at one year in open-label extension (OLE) comparable to 63% at 12 weeks in Phase 2 Avail™ trial
MBX Biosciences Transcript: AGM 2026
The meeting covered director elections and auditor ratification, with all proposals approved by stockholders. Voting procedures were clearly outlined, and final results will be reported in official filings.
MBX Biosciences Transcript: Jefferies Global Healthcare Conference 2026
The conference highlighted a robust clinical pipeline leveraging a validated PEP platform, with key programs in obesity and hypoparathyroidism advancing toward pivotal milestones. Once-weekly and monthly dosing strategies aim to improve patient adherence and tolerability, with upcoming data at ENDO and further obesity results expected in Q4.
MBX Biosciences to Host Virtual Investor Event to Discuss Once-Weekly Canvuparatide Presentations at ENDO 2026
CARMEL, Ind., June 01, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel pre...
MBX Biosciences to Present at the Jefferies 2026 Global Healthcare Conference in New York City
CARMEL, Ind. and BURLINGTON, Mass.
MBX Biosciences price target raised to $56 from $50 at Stifel
Stifel raised the firm’s price target on MBX Biosciences (MBX) to $56 from $50 and keeps a Buy rating on the shares following the company’s investor day meeting. Published first…
MBX Biosciences price target raised to $70 from $66 at Barclays
Barclays raised the firm’s price target on MBX Biosciences (MBX) to $70 from $66 and keeps an Overweight rating on the shares. The MBX 4291 data in obesity is early…
MBX Biosciences price target raised to $86 from $76 at Citizens
Citizens raised the firm’s price target on MBX Biosciences (MBX) to $86 from $76 and keeps an Outperform rating on the shares. MBX Biosciences reported encouraging early data for MBX…
MBX Biosciences price target raised to $70 from $50 at Truist
Truist analyst Srikripa Devarakonda raised the firm’s price target on MBX Biosciences (MBX) to $70 from $50 and keeps a Buy rating on the shares. The firm is updating its…
MBX Biosciences Transcript: Status update
MBX 4291, a once-monthly GLP-1/GIP co-agonist, showed 7% mean weight loss and strong tolerability in phase I, with top-line 12-week MAD results expected in Q4. The pipeline includes a multi-mechanism amycretin and a triple agonist, supported by robust financials and a focus on patient-centric, flexible dosing.
MBX Biosciences Press release: Status update
MBX Biosciences issued a press release on May 11, 2026, disclosing material business information to investors.
MBX Biosciences Slides: Status update
MBX Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on May 11, 2026.
MBX Biosciences Phase 1 data supports once-monthly dosing for MBX 4291
MBX Biosciences (MBX) announced multiple updates on its obesity portfolio, including preliminary blinded Phase 1 data for MBX 4291, a GLP-1/GIP co-agonist prodrug for obesity, which demonstrate a phar...
MBX Biosciences Provides Obesity Portfolio Update Including Initial Phase 1 Data for MBX 4291 Supporting Potential for Once-Monthly Dosing
Preliminary blinded data from ongoing Phase 1 trial demonstrated mean weight loss of 7% (range 0-16%) at 8 weeks in first MAD Part B cohort (n=8, including 2 placebo)
MBX Biosciences Proxy statement: Proxy filing
MBX Biosciences filed a proxy statement on May 8, 2026, providing details for shareholder voting and corporate governance matters.
MBX Biosciences reports Q1 EPS (51c), consensus (58c)
“We continue to make excellent progress across our pipeline in 2026, including advancement toward initiation of our Phase 3 trial of once-weekly canvuparatide following a successful End-of-Phase 2 mee...
MBX Biosciences appoints Mark Soued as chief commercial officer.
MBX Biosciences (MBX) announced the appointment of Mark Soued as chief commercial officer. Most recently, Soued served as senior VP, head of U.S. at Alnylam Pharmaceuticals (ALNY). Published first on…
MBX Biosciences Reports First Quarter 2026 Financial Results and Corporate Highlights
Results from Phase 2 trial of once-weekly canvuparatide accepted for oral presentation at ENDO in June 2026 Phase 3 trial of once-weekly canvuparatide on track to initiate in Q3 2026 Appointment of Ma...
MBX Biosciences Announces Appointment of Mark Soued as Chief Commercial Officer and Inducement Grant Award
CARMEL, Ind. and BURLINGTON, Mass.
MBX Biosciences Quarterly report: Q1 2026
MBX Biosciences has published its Q1 2026 quarterly earnings report on May 7, 2026.
MBX Biosciences Earnings release: Q1 2026
MBX Biosciences released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
MBX Biosciences to Host In-Person and Virtual Obesity Day on May 11, 2026 to Discuss Expanding Obesity Portfolio
CARMEL, Ind. and BURLINGTON, Mass.
MBX Biosciences Proxy statement: Proxy filing
MBX Biosciences filed a proxy statement on April 22, 2026, providing details for shareholder voting and corporate governance matters.
MBX Biosciences Proxy statement: Proxy filing
MBX Biosciences filed a proxy statement on April 22, 2026, providing details for shareholder voting and corporate governance matters.
MBX Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CARMEL, Ind., April 03, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel pr...